Pharmaceutical drugs and medicines are essential to modern healthcare, and in the Philippines, public healthcare facilities acquire these through the Philippine Government E-Procurement System (PhilGEPS). Economic theory and existing empirical studies show that pooled procurement can reduce unit prices for certain drugs and medicines, wherein pooled procurement occurs when buyers of the same product consolidate their separate orders into one single order. However, extensive research focusing on price-quantity relationships in the Philippine market is yet to be done. Moreover, the effects of pooled procurement on each drug have yet to be explored. As such, this study determines the extent of price changes in drugs and medicines if pooled procurement were implemented for pharmaceuticals in the Philippines. This was done using pharmaceutical bids across 2010 to 2021 from the PhilGEPS database, after pre-processing steps such as item label corrections using fuzzy match algorithms and price conversions to their equivalents in 2012 in consideration of Philippine peso inflation data. Afterwards, modeling price and quantity data was performed for 273 different medicines using the ordinary least squares (OLS) regression algorithm. The results of the modeling showed that the unit prices of 37 drugs and medicines would decrease by a median average of 18.31% and a mean average of 20.31% should orders be pooled, thereby benefiting from pooled procurement. Moreover, most of these 37 pharmaceuticals fall under the following therapeutic areas: “Anti-Infectives for Systemic Use”, “Cardiovascular System”, or “Nervous System”. Such information may help develop recommendations for policymakers regarding which pharmaceutical orders are most appropriate for pooling in pilot runs of pooled procurement systems.

1.
NHS
,
Epilepsy Treatment
, WWW document, (https://www.nhs.uk/conditions/epilepsy/treatment/).
3.
J. W.
Park
,
P. N.
Lagniton
,
Y.
Liu
, and
R. H.
Xu
,
Int. J. Biol. Sci.
17
(
6
),
1446
(
2021
).
4.
K.
Lambojon
et al,
Int. J. Environ. Res. Public Health.
17
(
14
),
5242
(
2020
).
5.
A. J.
Delima
and
M. T.
Lumintac
,
Int. J. Recent Technology and Engineering.
8
,
1761
(
2019
).
6.
J. D.
Urrutia
et al,
TURCOMAT.
12
(
3
),
5297
(
2021
).
7.
M.
Huff-Rousselle
,
Social Science Medicine.
75
(
9
),
1572
(
2012
).
8.
K.
Millington
and
M.
Bhardwaj
,
Evidence and Experience of Procurement in Health Sector Decentralisation
. (
K4D
,
United Kingdom
,
2017
).
9.
P.
Dubois
,
Y.
Lefouili
, and
S.
Straub
,
European Economic Review
132
,
103655
(
2021
).
10.
S. W.
Kim
and
J.
Skordis-Worrall
,
Health Policy and Planning.
32
(
4
),
516
(
2017
).
11.
Official Gazette of the Republic of the Philippines
,
Implementing Rules and Regulations of Republic Act No. 9184
, WWW document, (https://www.officialgazette.gov.ph/2016/08/29/implementing-rules-and-regulations-of-republic-act-no-9184/).
12.
Philippine Department of Health Pharmaceutical Division
,
Philippine National Formulary
, WWW document (https://pharma.doh.gov.ph/the-philippine-national-formulary/#).
13.
FDA Philippines
(
2022
). “
All drug industries
”,
Food and Drug Administration Philippines, Dataset.
https://verification.fda.gov.ph/ALL_DRUG_INDUSTRYlist.php
14.
PSA
,
PSGC Second Quarter 2021 Updates: Correction of Names of 17 Barangays
, WWW Document, (https://psa.gov.ph/content/psgc-second-quarter-2021-updates-correction-names-17-barangays).
15.
Philippine Department of Health
,
Drug Price Reference Index
, WWW document (https://dpri.doh.gov.ph/downloads/2021_feb_dpri.pdf).
16.
PSA
(
2022
), “
Consumer price index for all income households by commodity group
”,
PSA OpenSTAT.
https://openstat.psa.gov.ph/PXWeb/pxweb/en/DB/DB2MPICPI2012/0012M4ACPI1.px/?rxid=ad75e7b0-b50c-4dde-be64-a7d367b7888c
This content is only available via PDF.
You do not currently have access to this content.